Castle Biosciences
CSTL
159 hedge funds and large institutions have $916M invested in Castle Biosciences in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 49 reducing their positions, and 48 closing their positions.
41% more call options, than puts
Call options by funds: $313K | Put options by funds: $222K
31% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 49
0.63% less ownership
Funds ownership: 85.43% → 84.8% (-0.63%)
15% less funds holding
Funds holding: 188 → 159 (-29)
35% less capital invested
Capital invested by funds: $1.41B → $916M (-$498M)
56% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 48
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$32.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.8M |
| 3 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$18.4M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$15M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$9.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$44.1M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$24.2M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$23.8M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$15.1M |
| 5 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$9.84M |
CSTL Hedge Fund Activity: Q4 2021 in Review
159 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2021, worth a combined $916M — down 35% from $1.41B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of CSTL and 21 opened new positions — a net loss of 27 holders — while 49 trimmed existing stakes and 64 added.
The largest buyer was Wasatch Advisors, adding an estimated $32.5M. The largest seller was ARK Investment Management, cutting an estimated $44.1M.
- 159 institutional investors held Castle Biosciences (CSTL) as of Q4 2021, down from 188 in Q3 2021.
- Funds reported $916M of Castle Biosciences stock for Q4 2021, down 35% quarter-over-quarter.
- 21 funds opened new Castle Biosciences positions in Q4 2021 and 48 closed out, a net change of -27 holders.
- The largest Castle Biosciences buyer in Q4 2021 was Wasatch Advisors, an estimated $32.5M added.
- The largest Castle Biosciences seller in Q4 2021 was ARK Investment Management, an estimated $44.1M sold.
Based on aggregated 13F filings for Q4 2021.